An interventional study of AQUABEAM System and Transurethral Resection of the Prostate (TURP) in Benign Prostatic Hyperplasia (BPH), sponsored by PROCEPT BioRobotics. Completed at 17 sites in 4 countries. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by PROCEPT BioRobotics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 50th largest by enrollment of the 150 interventional ones that give a count, is one of 8 that started in 2015, is one of 63 with no phase, and was the 92nd registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 184 is above the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 201 across the 37 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 188 have an industry lead sponsor. The 10 most frequent:
PROCEPT BioRobotics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
PROCEPT BioRobotics has 9 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS). The primary endpoints for safety and effectiveness were measured at 3 and 6 months, respectively, and subjects were followed out to 5 years to collect long-term clinical data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AQUABEAM System
Device: AQUABEAM System
Transurethral Resection of the Prostate (TURP)
Procedure: Transurethral Resection of the Prostate (TURP)
The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability)
The primary safety endpoint is the proportion of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment. Note that the Clavien-Dindo classification scheme is for grading postoperative complications not events that reflect lack of effective treatment. Results are presented as a percentage rounded to the whole number.
Time frame: Three months post-treatment
Change Score of IPSS Questionnaire Between Baseline and 6 Months
The primary effectiveness endpoint is the IPSS change score from baseline to 6 months. International Prostate Symptom Score (IPSS) ranges from 0 to 35. A higher score indicates a worse outcome.
Time frame: Six months post-treatment
Long-term Effectiveness as Measured by International Prostate Symptom Score (IPSS) at 60 Months
Change score of International Prostate Symptom Score (IPSS) at 60 months as compared to baseline. Score range is from 0 to 35, with a low score associated with more favorable outcomes. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.
Time frame: 60 months following original surgical intervention
International Prostate Symptom Score (IPSS) at 60 Months
International Prostate Symptom Score (IPSS) at 60 months. Score range is from 0 to 35, with a low score associated with more favorable outcomes.
Time frame: 60 months following original surgical intervention
International Prostate Symptom Score Quality of Life (IPSS-QoL) at 60 Months
International Prostate Symptom Score Quality of Life (IPSS-QoL) sub-score. Score range is from 0 to 6, with a low score associated with more favorable outcomes.
Time frame: 60 months following original surgical intervention
Change in Maximum Urinary Flow Rate (Qmax) at 60 Months From Baseline
Change in Uroflowmetry measurement of voided urine (in milliliters) per unit of time (in seconds) at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.
Time frame: 60 months following original surgical intervention
Change in Post-void Residual (PVR) at 60 Months From Baseline
Change in Post-void residual (PVR) urine test at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.
Time frame: 60 months following original surgical intervention
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 116 | 65 |
| Completed | 116 | 65 |
| Not completed | 0 | 0 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 116 | 65 |
| Completed | 116 | 65 |
| Not completed | 0 | 0 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 116 | 65 |
| Completed | 116 | 65 |
| Not completed | 0 | 0 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 116 | 65 |
| Completed | 116 | 65 |
| Not completed | 0 | 0 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 116 | 65 |
| Completed | 116 | 63 |
| Not completed | 0 | 2 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 116 | 63 |
| Completed | 115 | 61 |
| Not completed | 1 | 2 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 115 | 61 |
| Completed | 112 | 60 |
| Not completed | 3 | 1 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 112 | 60 |
| Completed | 97 | 55 |
| Not completed | 15 | 5 |
| Milestone | Treatment | Active Comparator |
|---|---|---|
| Started | 97 | 55 |
| Completed | 58 | 32 |
| Not completed | 39 | 23 |
The primary safety endpoint is the proportion of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment. Note that the Clavien-Dindo classification scheme is for grading postoperative complications not events that reflect lack of effective treatment. Results are presented as a percentage rounded to the whole number.
| percentage of participants | Treatment | Active Comparator |
|---|---|---|
| Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability) | 26 (18.2 to 34.8) | 42 (29.4 to 54.4) |
The primary effectiveness endpoint is the IPSS change score from baseline to 6 months. International Prostate Symptom Score (IPSS) ranges from 0 to 35. A higher score indicates a worse outcome.
| score on a scale | Treatment | Active Comparator |
|---|---|---|
| Change Score of IPSS Questionnaire Between Baseline and 6 Months | -16.9 ± 6.6 | -15.1 ± 7.9 |
Change score of International Prostate Symptom Score (IPSS) at 60 months as compared to baseline. Score range is from 0 to 35, with a low score associated with more favorable outcomes. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.
| change in score on a scale | Treatment | Active Comparator |
|---|---|---|
| Long-term Effectiveness as Measured by International Prostate Symptom Score (IPSS) at 60 Months | -15.1 ± 6.6 | -13.2 ± 8.2 |
International Prostate Symptom Score (IPSS) at 60 months. Score range is from 0 to 35, with a low score associated with more favorable outcomes.
| score on a scale | Treatment | Active Comparator |
|---|---|---|
| International Prostate Symptom Score (IPSS) at 60 Months | 5.5 (1 to 28) | 6 (1 to 28) |
International Prostate Symptom Score Quality of Life (IPSS-QoL) sub-score. Score range is from 0 to 6, with a low score associated with more favorable outcomes.
| score on a scale | Treatment | Active Comparator |
|---|---|---|
| International Prostate Symptom Score Quality of Life (IPSS-QoL) at 60 Months | 1.6 ± 1.4 | 1.6 ± 1.5 |
Change in Uroflowmetry measurement of voided urine (in milliliters) per unit of time (in seconds) at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.
| mL/s | Treatment | Active Comparator |
|---|---|---|
| Change in Maximum Urinary Flow Rate (Qmax) at 60 Months From Baseline | 8.7 ± 9.1 | 6.3 ± 7.5 |
Change in Post-void residual (PVR) urine test at 60 Months from Baseline. Change score is calculated from two time points as the value at the 60 months point minus the value at the baseline.
| mL | Treatment | Active Comparator |
|---|---|---|
| Change in Post-void Residual (PVR) at 60 Months From Baseline | -62 ± 86 | -82 ± 94 |
Collected over 5 years. Non-serious events are listed at a 1.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 4/116 (3.4%) | 24/116 (20.7%) | 75/116 (64.7%) |
| Active Comparator | 1/65 (1.5%) | 14/65 (21.5%) | 53/65 (81.5%) |
| Event | Treatment | Active Comparator |
|---|---|---|
| BleedingRenal and urinary disorders | 4/116 | 4/65 |
| Urinary urgency/frequency/difficulty/leakage (non-procedure-related)Renal and urinary disorders | 5/116 | 1/65 |
| Cardiac (non-procedure-related)Cardiac disorders | 4/116 | 2/65 |
| Urinary retentionRenal and urinary disorders | 3/116 | 2/65 |
| Non-urologicGeneral disorders | 3/116 | 0/65 |
| Other bleeding (non-procedure-related)General disorders | 2/116 | 0/65 |
| Urinary tract infection (non-procedure-related)Renal and urinary disorders | 2/116 | 0/65 |
| Bladder neck contracture (non-procedure-related)Renal and urinary disorders | 1/116 | 1/65 |
| Penial infection (non-procedure-related)Infections and infestations | 0/116 | 1/65 |
| Prostate cancer (non-procedure-related)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/116 | 1/65 |
| Event | Treatment | Active Comparator |
|---|---|---|
| Retrograde ejaculationReproductive system and breast disorders | 8/116 | 16/65 |
| Urinary urgency/frequency/difficulty/leakage (non-procedure-related)Renal and urinary disorders | 18/116 | 14/65 |
| Urinary urgency/frequency/difficulty/leakageRenal and urinary disorders | 9/116 | 9/65 |
| Non-urologicGeneral disorders | 16/116 | 7/65 |
| DysuriaRenal and urinary disorders | 14/116 | 6/65 |
| BleedingRenal and urinary disorders | 12/116 | 6/65 |
| Urinary tract infectionRenal and urinary disorders | 11/116 | 5/65 |
| Erectile Dysfunction (non-procedure-related)Reproductive system and breast disorders | 7/116 | 6/65 |
| Bleeding (non-procedure-related)Renal and urinary disorders | 5/116 | 5/65 |
| Urinary retention (non-procedure-related)Renal and urinary disorders | 4/116 | 5/65 |
| Age, Continuous(years) | Treatment | Active Comparator | Total |
|---|---|---|---|
| Mean | 66.0 ± 7.3 | 65.8 ± 7.2 | 65.9 ± 7.3 |
| Sex: Female, Male(Participants) | Treatment | Active Comparator | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 117 | 67 | 184 |
| Ethnicity (NIH/OMB)(Participants) | Treatment | Active Comparator | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 114 | 64 | 178 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Treatment | Active Comparator | Total |
|---|---|---|---|
| Asian | 3 | 2 | 5 |
| Hispanic | 2 | 3 | 5 |
| Black | 2 | 2 | 4 |
| White | 109 | 59 | 168 |
| Other | 1 | 0 | 1 |
| NA | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Treatment | Active Comparator | Total |
|---|---|---|---|
| New Zealand | 11 | 9 | 20 |
| United States | 61 | 32 | 93 |
| United Kingdom | 32 | 18 | 50 |
| Australia | 13 | 8 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Jul 2017, 20 months.
Results were first posted in Apr 2020, 2 years 8 months after primary completion.
Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's 20 months is below that.
Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PROCEPT BioRobotics